U.S., Jan. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07365059) titled 'Safety and Efficacy of GPRC5D CAR-T Cell Therapy in Relapsed/Refractory Plasma Cell Disorders' on Jan. 07.
Brief Summary: This study is an open-label, single-arm, dose-escalation and expansion, prospective clinical trial. It enrolls patients with relapsed/refractory plasma cell disorders, administers GPRC5D CAR-T cell therapy, follows up to observe adverse reactions after medication, collects relevant data on treatment efficacy, evaluates the safety and efficacy of CAR-T cells, and simultaneously investigates the cellular kinetic characteristics of CAR-T cells.
Study Start Date: Jan. 25
Study Type: INTERVENTIONAL
Condition:
Plas...